1
|
Yoen H, Chung HA, Lee SM, Kim ES, Moon WK, Ha SM. Hemorrhagic Complications Following Ultrasound-Guided Breast Biopsy: A Prospective Patient-Centered Study. Korean J Radiol 2024; 25:157-165. [PMID: 38288896 PMCID: PMC10831294 DOI: 10.3348/kjr.2023.0874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2023] [Revised: 11/13/2023] [Accepted: 11/29/2023] [Indexed: 02/01/2024] Open
Abstract
OBJECTIVE We aimed to evaluate the clinical and imaging factors associated with hemorrhagic complications and patient discomfort following ultrasound (US)-guided breast biopsy. MATERIALS AND METHODS We prospectively enrolled 94 patients who were referred to our hospital between June 2022 and December 2022 for US-guided breast biopsy. After obtaining informed consent, two breast radiologists independently performed US-guided breast biopsy and evaluated the imaging findings. A hemorrhagic complication was defined as the presence of bleeding or hematoma on US. The patients rated symptoms of pain, febrile sensation, swelling at the biopsy site, and dyspnea immediately, 20 minutes, and 2 weeks after the procedure on a visual analog scale, with 0 for none and 10 for the most severe symptoms. Additional details recorded included those of nausea, vomiting, bleeding, bruising, and overall satisfaction score. We compared the clinical symptoms, imaging characteristics, and procedural features between patients with and those without hemorrhagic complications. RESULTS Of 94 patients, 7 (7%) developed hemorrhagic complications, while 87 (93%) did not. The complication resolved with 20 minutes of manual compression, and no further intervention was required. Vascularity on Doppler examination (P = 0.008), needle type (P = 0.043), and lesion location (P < 0.001) were significantly different between the groups. Patients with hemorrhagic complications reported more frequent nausea or vomiting than those without hemorrhagic complications (29% [2/7] vs. 2% [2/87], respectively; P = 0.027). The overall satisfaction scores did not differ between the two groups (P = 0.396). After 2 weeks, all symptoms subsided, except bruising (50% 2/4 in the complication group and 25% [16/65] in the no-complication group). CONCLUSION US-guided breast biopsy is a safe procedure with a low complication rate. Radiologists should be aware of hemorrhagic complications, patient discomfort, and overall satisfaction related to this procedure.
Collapse
Affiliation(s)
- Heera Yoen
- Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea
| | - Hyun-Ah Chung
- Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea
| | - So-Min Lee
- Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea
| | - Eun-Sung Kim
- Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea
| | - Woo Kyung Moon
- Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea
- Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea
- Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea
| | - Su Min Ha
- Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea
- Department of Radiology, Seoul National University College of Medicine, Seoul, Republic of Korea
- Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea.
| |
Collapse
|
2
|
Lewis JD, Groszkiewicz A, Hefelfinger L, Doherty A, Foringer A, Shaughnessy E, Heelan A, Brown AL. Clinically significant bleeding complications of percutaneous breast biopsy: 10-year analysis and a proposed management algorithm. Clin Imaging 2023; 104:110017. [PMID: 37979400 DOI: 10.1016/j.clinimag.2023.110017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 10/20/2023] [Accepted: 10/31/2023] [Indexed: 11/20/2023]
Abstract
PURPOSE Bleeding is a well-known risk of percutaneous breast biopsy, frequently controlled with manual pressure. However, significant bleeding complications may require further evaluation or intervention. Our objectives were to assess the rate, type, and periprocedural management of significant bleeding following percutaneous breast biopsy and to evaluate the success of any interventions. METHODS We retrospectively reviewed percutaneous breast biopsies at our institution over a 10-year period with documented post-biopsy bleeding complications in radiology reports. Patients were included if bleeding required intervention (interventional radiology [IR], surgery, or other), imaging follow-up, or clinical evaluation for symptoms. Additional data included patient demographics, anticoagulation, history of bleeding diathesis, biopsy details, bleeding symptoms, histopathology, and intervention details, if applicable. RESULTS Of 5820 unique patients who underwent percutaneous biopsy, 66 patients (66/5820; 1.1%) comprising 71 biopsy cases met inclusion for clinically significant bleeding with 5/71(7.0%) requiring surgery, 9/71(12.7%) requiring IR intervention, and 57/71(80.3%) requiring lower-acuity intervention including prolonged observation (5/57;7.0%), overnight admission (4/57;5.6%), aspiration (4/57;5.6%), lidocaine and suture (2/57;2.8%), primary care visit (7/57;10.0%), blood transfusion (1/57;1.4%), emergency room visit (6/57;8.5%), surgery consult (8/57;11.3%), IR consult (2/57;2.8%), and follow-up imaging (22/57;31.0%). Most patients requiring intervention by surgery or IR had acute signs of bleeding immediately after biopsy while most patients with delayed signs of bleeding required lower-acuity interventions. CONCLUSION Clinically significant bleeding is extremely rare after percutaneous breast biopsy and is most often managed non-surgically. Developing an institutional algorithm for management of bleeding complications that consults IR before surgery may help decrease the number of patients managed surgically.
Collapse
Affiliation(s)
- Jaime D Lewis
- Department of Surgery, University of Cincinnati Medical Center, 3188 Bellevue Avenue, Cincinnati, OH 45219, United States of America.
| | - Abigail Groszkiewicz
- University of Cincinnati College of Medicine, 3230 Eden Avenue, Cincinnati, OH 45267, United States of America.
| | - Leah Hefelfinger
- University of Cincinnati College of Medicine, 3230 Eden Avenue, Cincinnati, OH 45267, United States of America.
| | - Alexander Doherty
- University of Cincinnati College of Medicine, 3230 Eden Avenue, Cincinnati, OH 45267, United States of America.
| | - Alyssa Foringer
- University of Cincinnati College of Medicine, 3230 Eden Avenue, Cincinnati, OH 45267, United States of America.
| | - Elizabeth Shaughnessy
- Department of Surgery, University of Cincinnati Medical Center, 3188 Bellevue Avenue, Cincinnati, OH 45219, United States of America.
| | - Alicia Heelan
- Department of Surgery, University of Cincinnati Medical Center, 3188 Bellevue Avenue, Cincinnati, OH 45219, United States of America.
| | - Ann L Brown
- Department of Radiology, University of Cincinnati Medical Center, 3188 Bellevue Avenue, Cincinnati, OH 45219, United States of America.
| |
Collapse
|
3
|
Grażyńska A, Niewiadomska A, Owczarek AJ, Winder M, Hołda J, Zwolińska O, Barczyk-Gutkowska A, Lorek A, Kuźbińska A, Steinhof-Radwańska K. BIRADS 4 - Is it possible to downgrade lesions that do not enhance on recombinant contrast-enhanced mammography images? Eur J Radiol 2023; 167:111062. [PMID: 37643559 DOI: 10.1016/j.ejrad.2023.111062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Revised: 08/03/2023] [Accepted: 08/22/2023] [Indexed: 08/31/2023]
Abstract
PURPOSE Analysis of the morphology of lesions classified into the BI-RADS 4 category and assessment of the possibility of downgrade the BI-RADS category in those that did not show enhancement on recombinant contrast-enhanced mammography (CEM) images. METHOD The retrospective, single-center study included 528 patients who underwent a core needle biopsy performed from January 2017 to November 2022 due to a breast lesion classified as BI-RADS 4 on CEM. Patients' electronic records and imaging examinations were reviewed. Individual lesions were classified into the morphological categories of mass, non-mass, and microcalcifications. Sensitivity, specificity, positive as well as negative predictive values were calculated for the whole group and individual morphological categories. The influence of the lesions' diameter on the results was analyzed. RESULTS CEM NPV for the whole group was 93.9% (±95% CI: 90.0-96.4), for mass lesions 100% (±95% CI: 94.5-100), for non-mass lesions 97.8% (±95% CI: 87.0-99.9) and 87.9% (±95% CI: 80.3-93.0) for microcalcifications. Given that 230 out of 383 benign lesions were not contrast-enhancing, 60.1% of unnecessary CNBs would have been correctly avoided. CEM sensitivity for lesions < 20 mm was lower than for lesions ≥ 20 mm and was respectively 86.6% (±95% CI: 76.8-92.8) vs 94.6% (±95% CI: 86.0-98.2), respectively. CONCLUSION CEM is characterized by high sensitivity in the detection of malignant lesions in the case of lesions with mass and non-mass morphology. The high NPV for recombinant images suggests that in the case of these lesions, the lack of enhancement supports the benign nature of the lesion and may lead to a downgrade of the BI-RADS category.
Collapse
Affiliation(s)
- Anna Grażyńska
- Department of Radiology and Nuclear Medicine, Medical University of Silesia, Medyków 14, 40-752 Katowice, Poland.
| | - Agnieszka Niewiadomska
- Department of Radiology and Nuclear Medicine, Medical University of Silesia, Medyków 14, 40-752 Katowice, Poland
| | - Aleksander J Owczarek
- Department of Pathophysiology, Medical University of Silesia, Medyków 14, 40-752 Katowice, Poland
| | - Mateusz Winder
- Department of Radiology and Nuclear Medicine, Medical University of Silesia, Medyków 14, 40-752 Katowice, Poland
| | - Jakub Hołda
- Department of Radiology and Nuclear Medicine, Medical University of Silesia, Medyków 14, 40-752 Katowice, Poland; Department of Anatomy, Jagiellonian University Medical College, Kopernika 12, 31-034 Cracow, Poland
| | - Olga Zwolińska
- Department of Radiology and Nuclear Medicine, Medical University of Silesia, Medyków 14, 40-752 Katowice, Poland
| | - Anna Barczyk-Gutkowska
- Department of Radiology and Nuclear Medicine, Medical University of Silesia, Medyków 14, 40-752 Katowice, Poland
| | - Andrzej Lorek
- Department of Oncological Surgery, Prof. Kornel Gibiński Independent Public Central Clinical Hospital, Ceglana 35, 40-514 Katowice, Poland
| | - Aleksandra Kuźbińska
- Department of Pathomorfology, Medical University of Silesia, Medyków 14, 40-752 Katowice, Poland
| | - Katarzyna Steinhof-Radwańska
- Department of Radiology and Nuclear Medicine, Medical University of Silesia, Medyków 14, 40-752 Katowice, Poland.
| |
Collapse
|
4
|
Pansa E, Guzzardi G, Santocono S, Carriero A. Vascular Complications following Vacuum-Assisted Breast Biopsy (VABB): A Case Report and Review of the Literature. Tomography 2023; 9:1246-1253. [PMID: 37489467 PMCID: PMC10366872 DOI: 10.3390/tomography9040099] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 06/05/2023] [Accepted: 06/21/2023] [Indexed: 07/26/2023] Open
Abstract
INTRODUCTION Vacuum-assisted breast biopsy (VABB) has been evaluated as a minimally invasive, safe, and accurate procedure with low complication risks; the most frequent one is the mild/moderate hematoma, which occurs with a low-frequency rate, and the majority of patients who experienced it can be treated successfully with only manual compression and dressing. Although cases of uncontrollable catastrophic bleeding are exceedingly rare, local breast vessel involvement is a concrete risk, even in patients with no bleeding propensity. CASE PRESENTATION In this article, we aimed to describe a 60 years-old woman who, following VABB, experienced a massive hematoma without external bleeding and was successfully treated with embolization. The woman was called back for a cluster of suspicious microcalcifications identified in the left breast's upper-outer quadrant; however, following histopathological analysis, the few samples collected were negative. She had a silent past medical history, 100% performance status, and no active pharmacotherapy. Approximately 15-30 min after VABB, the patient complained of weakness, pain, and lipothymia. A physical examination revealed a massive hematoma without external bleeding. Clinical data reported PaO 65/40 mmHg and blood chemistry Hb < 10 g/dL. The emergency team was alerted to stabilize the patient, and after that, the breast hemorrhage was controlled by endovascular embolization. Despite this being a rare occurrence, it is important to draw up and follow an appropriate protocol to ensure proper patient management and early treatment. DISCUSSION This case illustrates the prompt and accurate management of a rare complication following VABB. Due to the very high number of patients undergoing this particular procedure, we aim to point out the concrete risk of vascular injury; other similar cases are described to support our thesis and provide different clinical manifestations of this rare occurrence.
Collapse
Affiliation(s)
- Ernesto Pansa
- Specializzando in Radiodiagnostica UPO, 28100 Novara, Italy
| | | | | | | |
Collapse
|
5
|
Watson JF, Radic R, Frost R, Paton S, Kessell MA, Dessauvagie BF, Taylor DB. Vacuum-assisted excision biopsy for definitive diagnosis of breast lesions of uncertain malignant potential (B3 lesions) on core biopsy - A single centre Western Australian experience. J Med Imaging Radiat Oncol 2023. [PMID: 36596982 DOI: 10.1111/1754-9485.13502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2022] [Accepted: 12/07/2022] [Indexed: 01/05/2023]
Abstract
INTRODUCTION In Australia, the usual approach to breast lesions where core biopsy returns an uncertain result ("B3" breast lesion) is to perform surgical diagnostic open biopsy (DOB). This is associated with patient time off work, costs of hospital admission, risks of general anaesthesia and surgical complications. The majority of B3 lesions return benign results following surgery. Vacuum assisted excision biopsy (VAEB) is a less invasive, lower cost alternative, and is standard of care for selected B3 lesions in the United Kingdom. Similar use of VAEB in Australia, could save many women unnecessary surgery. The aim of this study was to document our experience during the introduction of VAEB as an alternative to DOB for diagnosis of selected B3 lesions. METHODS The multidisciplinary team developed an agreed VAEB pathway for selected B3 lesions. Technically accessible papillary lesions, mucocele-like lesions and radial scars without atypia measuring ≤ 15mm were selected. RESULTS Over a 7 month period, 18 women with 20 B3 lesions were offered VAEB. 16 women (18 lesions) chose VAEB over DOB. Papillomas were the commonest lesion type. All lesions were successfully sampled: 17/18 were benign. One lesion (6%) was upgraded to malignancy (ductal carcinoma in situ on VAEB, invasive ductal carcinoma at surgery). No major complications occurred. Patient satisfaction was high: 15/16 respondents would again choose VAEB over surgery. CONCLUSION VAEB is a patient-preferred, safe, well-tolerated, lower-cost alternative to DOB for definitive diagnosis of selected B3 breast lesions.
Collapse
Affiliation(s)
- Jessica Frances Watson
- Department of Diagnostic and Interventional Radiology, Royal Perth Hospital, Perth, Western Australia, Australia.,Nepean Hospital, Sydney, New South Wales, Australia
| | - Rose Radic
- Department of Diagnostic and Interventional Radiology, Royal Perth Hospital, Perth, Western Australia, Australia
| | - Rosanna Frost
- Department of Diagnostic and Interventional Radiology, Royal Perth Hospital, Perth, Western Australia, Australia.,Royal United Hospitals Bath, NHS Foundation Trust, Bath, UK
| | - Sarah Paton
- Department of Diagnostic and Interventional Radiology, Royal Perth Hospital, Perth, Western Australia, Australia
| | - Meredith Anita Kessell
- Department of Diagnostic and Interventional Radiology, Royal Perth Hospital, Perth, Western Australia, Australia
| | - Benjamin Frederik Dessauvagie
- Department of Diagnostic and Interventional Radiology, Royal Perth Hospital, Perth, Western Australia, Australia.,PathWest Laboratory Medicine WA, Fiona Stanley Hospital, Perth, Western Australia, Australia.,University of Western Australia Medical School, Perth, Western Australia, Australia
| | - Donna Blanche Taylor
- Department of Diagnostic and Interventional Radiology, Royal Perth Hospital, Perth, Western Australia, Australia.,University of Western Australia Medical School, Perth, Western Australia, Australia.,BreastScreen WA, Perth, Western Australia, Australia
| |
Collapse
|
6
|
Loving VA, Johnston BS, Reddy DH, Welk LA, Lawther HA, Klein SC, Cranford CM, Reed RC, Rangan P, Morris MF. Antithrombotic Therapy and Hematoma Risk during Image-guided Core-Needle Breast Biopsy. Radiology 2023; 306:79-86. [PMID: 35997610 DOI: 10.1148/radiol.220548] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Background For image-guided core-needle breast biopsy (CNBB), it remains unclear whether antithrombotic medication should be withheld because of hematoma risk. Purpose To determine hematoma risk after CNBB in patients receiving antithrombotic medication and to stratify risk by antithrombotic type. Materials and Methods This HIPAA-compliant retrospective study included US-, stereotactic-, or MRI-guided CNBBs performed across six academic and six private practices between April 2019 and April 2021. Patients were instructed to continue antithrombotic medications, forming two groups: antithrombotic and nonantithrombotic. Hematomas were defined as new biopsy-site masses with a diameter of 2 cm or larger on postprocedure mammograms. Hematomas were considered clinically significant if management involved an intervention other than manual compression. Patient age, type of antithrombotic medication, practice type, image guidance modality, needle gauge and type, and outcome of pathologic analysis were recorded. Multivariable logistic regression analysis was used to analyze variables associated with hematomas. Results A total of 3311 biopsies were performed in 2664 patients (median age, 60 years; IQR, 48-70 years; 2658 women). The nonantithrombotic group included 2788 biopsies, and the antithrombotic group included 523 biopsies (328 low-dose aspirin, 73 full-dose antiplatelet drugs, 51 direct oral anticoagulants, 36 warfarin, 32 daily nonsteroidal anti-inflammatory drugs, three heparin or enoxaparin). The antithrombotic group had a higher overall hematoma rate (antithrombotic group: 49 of 523 biopsies [9.4%], nonantithrombotic group: 172 of 2788 biopsies [6.2%]; P = .007), but clinically significant hematoma rates were not different (antithrombotic group: two of 523 biopsies [0.4%], nonantithrombotic group: one of 2788 biopsies [0.04%]; P = .07). At multivariable analysis, age (odds ratio [OR], 1.02; 95% CI: 1.01, 1.03; P < .001), 9-gauge or larger needles (OR, 2.1; 95% CI: 1.28, 3.3; P = .003), and full-dose antiplatelet drugs (OR, 2.5; 95% CI: 1.29, 5.0; P = .007) were associated with higher hematoma rates. US guidance (OR, 0.26; 95% CI: 0.17, 0.40; P < .001) and 10-14-gauge needles (OR, 0.53; 95% CI: 0.36, 0.79; P = .002) were predictive of no hematoma. Conclusion Because clinically significant hematomas were uncommon, withholding antithrombotic medications before core-needle breast biopsy may be unnecessary. Postbiopsy hematomas were associated with full-dose antiplatelet drugs, patient age, and 9-gauge or larger needles. No association was found with other types of antithrombotic medication. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Chang and Yoen in this issue.
Collapse
Affiliation(s)
- Vilert A Loving
- From the Division of Diagnostic Imaging, Banner MD Anderson Cancer Center, 2940 E Banner Gateway Dr, Suite 150, Gilbert, AZ 85234 (V.A.L., B.S.J., D.H.R., L.A.W., H.A.L., S.C.K., M.F.M.); Banner Imaging, Glendale, Ariz (C.M.C.); Radiology Imaging Associates, Englewood, Colo (R.C.R.); Division of Clinical Data Analytics and Decision Support, Department of Internal Medicine (P.R.), and Department of Radiology (M.F.M.), Banner-University Medical Center Phoenix, Phoenix, Ariz
| | - Brian S Johnston
- From the Division of Diagnostic Imaging, Banner MD Anderson Cancer Center, 2940 E Banner Gateway Dr, Suite 150, Gilbert, AZ 85234 (V.A.L., B.S.J., D.H.R., L.A.W., H.A.L., S.C.K., M.F.M.); Banner Imaging, Glendale, Ariz (C.M.C.); Radiology Imaging Associates, Englewood, Colo (R.C.R.); Division of Clinical Data Analytics and Decision Support, Department of Internal Medicine (P.R.), and Department of Radiology (M.F.M.), Banner-University Medical Center Phoenix, Phoenix, Ariz
| | - Denise H Reddy
- From the Division of Diagnostic Imaging, Banner MD Anderson Cancer Center, 2940 E Banner Gateway Dr, Suite 150, Gilbert, AZ 85234 (V.A.L., B.S.J., D.H.R., L.A.W., H.A.L., S.C.K., M.F.M.); Banner Imaging, Glendale, Ariz (C.M.C.); Radiology Imaging Associates, Englewood, Colo (R.C.R.); Division of Clinical Data Analytics and Decision Support, Department of Internal Medicine (P.R.), and Department of Radiology (M.F.M.), Banner-University Medical Center Phoenix, Phoenix, Ariz
| | - Leslie A Welk
- From the Division of Diagnostic Imaging, Banner MD Anderson Cancer Center, 2940 E Banner Gateway Dr, Suite 150, Gilbert, AZ 85234 (V.A.L., B.S.J., D.H.R., L.A.W., H.A.L., S.C.K., M.F.M.); Banner Imaging, Glendale, Ariz (C.M.C.); Radiology Imaging Associates, Englewood, Colo (R.C.R.); Division of Clinical Data Analytics and Decision Support, Department of Internal Medicine (P.R.), and Department of Radiology (M.F.M.), Banner-University Medical Center Phoenix, Phoenix, Ariz
| | - Hannah A Lawther
- From the Division of Diagnostic Imaging, Banner MD Anderson Cancer Center, 2940 E Banner Gateway Dr, Suite 150, Gilbert, AZ 85234 (V.A.L., B.S.J., D.H.R., L.A.W., H.A.L., S.C.K., M.F.M.); Banner Imaging, Glendale, Ariz (C.M.C.); Radiology Imaging Associates, Englewood, Colo (R.C.R.); Division of Clinical Data Analytics and Decision Support, Department of Internal Medicine (P.R.), and Department of Radiology (M.F.M.), Banner-University Medical Center Phoenix, Phoenix, Ariz
| | - Shayna C Klein
- From the Division of Diagnostic Imaging, Banner MD Anderson Cancer Center, 2940 E Banner Gateway Dr, Suite 150, Gilbert, AZ 85234 (V.A.L., B.S.J., D.H.R., L.A.W., H.A.L., S.C.K., M.F.M.); Banner Imaging, Glendale, Ariz (C.M.C.); Radiology Imaging Associates, Englewood, Colo (R.C.R.); Division of Clinical Data Analytics and Decision Support, Department of Internal Medicine (P.R.), and Department of Radiology (M.F.M.), Banner-University Medical Center Phoenix, Phoenix, Ariz
| | - Caroline M Cranford
- From the Division of Diagnostic Imaging, Banner MD Anderson Cancer Center, 2940 E Banner Gateway Dr, Suite 150, Gilbert, AZ 85234 (V.A.L., B.S.J., D.H.R., L.A.W., H.A.L., S.C.K., M.F.M.); Banner Imaging, Glendale, Ariz (C.M.C.); Radiology Imaging Associates, Englewood, Colo (R.C.R.); Division of Clinical Data Analytics and Decision Support, Department of Internal Medicine (P.R.), and Department of Radiology (M.F.M.), Banner-University Medical Center Phoenix, Phoenix, Ariz
| | - R Christopher Reed
- From the Division of Diagnostic Imaging, Banner MD Anderson Cancer Center, 2940 E Banner Gateway Dr, Suite 150, Gilbert, AZ 85234 (V.A.L., B.S.J., D.H.R., L.A.W., H.A.L., S.C.K., M.F.M.); Banner Imaging, Glendale, Ariz (C.M.C.); Radiology Imaging Associates, Englewood, Colo (R.C.R.); Division of Clinical Data Analytics and Decision Support, Department of Internal Medicine (P.R.), and Department of Radiology (M.F.M.), Banner-University Medical Center Phoenix, Phoenix, Ariz
| | - Pooja Rangan
- From the Division of Diagnostic Imaging, Banner MD Anderson Cancer Center, 2940 E Banner Gateway Dr, Suite 150, Gilbert, AZ 85234 (V.A.L., B.S.J., D.H.R., L.A.W., H.A.L., S.C.K., M.F.M.); Banner Imaging, Glendale, Ariz (C.M.C.); Radiology Imaging Associates, Englewood, Colo (R.C.R.); Division of Clinical Data Analytics and Decision Support, Department of Internal Medicine (P.R.), and Department of Radiology (M.F.M.), Banner-University Medical Center Phoenix, Phoenix, Ariz
| | - Michael F Morris
- From the Division of Diagnostic Imaging, Banner MD Anderson Cancer Center, 2940 E Banner Gateway Dr, Suite 150, Gilbert, AZ 85234 (V.A.L., B.S.J., D.H.R., L.A.W., H.A.L., S.C.K., M.F.M.); Banner Imaging, Glendale, Ariz (C.M.C.); Radiology Imaging Associates, Englewood, Colo (R.C.R.); Division of Clinical Data Analytics and Decision Support, Department of Internal Medicine (P.R.), and Department of Radiology (M.F.M.), Banner-University Medical Center Phoenix, Phoenix, Ariz
| |
Collapse
|
7
|
Contrast-enhanced mammography-guided biopsy: technical feasibility and first outcomes. Eur Radiol 2022; 33:417-428. [PMID: 35895121 DOI: 10.1007/s00330-022-09021-w] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Revised: 05/23/2022] [Accepted: 06/30/2022] [Indexed: 12/19/2022]
Abstract
OBJECTIVES To evaluate the feasibility of contrast-enhanced mammography (CEM)-guided biopsy at Hospital del Mar, a Spanish university hospital. METHODS We retrospectively reviewed all consecutive women with a suspicious enhancing finding eligible for CEM-guided biopsy, who were prospectively enrolled in a pre-marketing clinical validation and feasibility study (October 2019 to September 2021). CEM-guided biopsy is a stereotactic-based procedure that, by using intravenous iodinated contrast media administration and dual-energy acquisition, provides localisation of enhancing lesions. All the biopsies were performed using a vacuum-assisted device. We collected procedural characteristics (patient position and type of approach), and histopathological results. Feasibility endpoints included success (visualisation of the enhancing lesion, post-procedural biopsy changes and clip placement), procedural time, number of scout acquisitions and complications. RESULTS A total of 66 suspicious enhancing lesions (18.0% foci, 44.0% mass, 38.0% non-mass enhancement; median size 8.5 mm) in 64 patients (median age 59 years, mostly minimal [48.4%] or mild [32.8%] background parenchymal enhancement) were referred for CEM-guided biopsy in the study period. The success rate was 63/66 (95.4%). Amongst successful procedures, patients were most frequently seated (52/63, 82.5%) and the preferred approach was horizontal (48/63, 76.2%). Median total time per procedure was 15 min. Median number of acquisitions needed before targeting was 2 (range 1-4). Complications consisted of hematoma (17/63, 27%) and vasovagal reaction (2/63, 3.2%). At histology, the malignancy rate was 25/63 (39.7%). CONCLUSION In this first patient series, CEM-guided breast biopsy was feasible, with success and complication rates similar to those previously reported for magnetic resonance guidance. KEY POINTS • CEM may be used to guide biopsy of enhancing lesions through a stereotactic-based procedure combined with intravenous iodinated contrast media administration and dual-energy acquisition. • In this first patient series (n = 64), the success rate of CEM-guided biopsy was above 95%, the only complications were hematoma (22.2%) and vasovagal reaction (3.2%), and median total time per procedure was 15 min. • CEM-guided biopsy is feasible and could potentially be a widely available biopsy technique for enhancing-only lesions.
Collapse
|
8
|
Goudreau S, Grimm LJ, Srinivasan A, Net J, Yang R, Dialani V, Dodelzon K. Bleeding Complications After Breast Core-needle Biopsy-An Approach to Managing Patients on Antithrombotic Therapy. JOURNAL OF BREAST IMAGING 2022; 4:241-252. [PMID: 38416973 DOI: 10.1093/jbi/wbac020] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Indexed: 03/01/2024]
Abstract
Image-guided core-needle breast and axillary biopsy (CNB) is the standard-of-care procedure for the diagnosis of breast cancer. Although the risks of CNB are low, the most common complications include bleeding and hematoma formation. Post-procedural bleeding is of particular concern in patients taking antithrombotic therapy, but there is currently no widely established standard protocol in the United States to guide antithrombotic therapy management. In the face of an increasing number of patients taking antithrombotic therapy and with the advent of novel classes of anticoagulants, the American College of Radiology guidelines recommend that radiologists consider cessation of antithrombotic therapy prior to CNB on a case-by-case basis. Lack of consensus results in disparate approaches to patients on antithrombotic therapy undergoing CNB. There is further heterogeneity in recommendations for cessation of antithrombotic therapy based on the modality used for image-guided biopsy, target location, number of simultaneous biopsies, and type of antithrombotic agent. A review of the available data demonstrates the safety of continuing antithrombotic therapy during CNB while highlighting additional procedural and target lesion factors that may increase the risk of bleeding. Risk stratification of patients undergoing breast interventional procedures is proposed to guide both pre-procedural decision-making and post-procedural management. Radiologists should be aware of antithrombotic agent pharmacokinetics and strategies to minimize post-procedural bleeding to safely manage patients.
Collapse
Affiliation(s)
- Sally Goudreau
- University of Texas Southwestern Medical Center, Department of Radiology, Dallas, TX, USA
| | - Lars J Grimm
- Duke University Medical Center, Department of Radiology, Durham, NC, USA
| | | | - Jose Net
- University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA
| | - Roger Yang
- Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
| | - Vandana Dialani
- Beth Israel Lahey Health, Department of Radiology, Boston, MA, USA
| | - Katerina Dodelzon
- Weill Cornell at New York-Presbyterian, Department of Radiology, New York, NY, USA
| |
Collapse
|
9
|
Halicek M, Qian C, Raissi D, Wang X, Chornenkyy Y, Bates WB, Winkler M. Rapid 3D reconstruction guided embolization for catastrophic bleeding following vacuum assisted breast biopsy; A case report and review of the literature. Radiol Case Rep 2021; 16:3593-3596. [PMID: 34603567 PMCID: PMC8463745 DOI: 10.1016/j.radcr.2021.08.053] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2021] [Revised: 08/19/2021] [Accepted: 08/20/2021] [Indexed: 11/27/2022] Open
Abstract
The most clinically significant complication associated with stereotactic core needle biopsy of the breast is hematoma formation, which only occurs in less than 1% of biopsies and may require treatment. Cases of uncontrollable bleeding, refractory to repeated compression, resulting from biopsy are exceedingly rare. We present a case of catastrophic, uncontrollable bleeding and large hematoma formation resulting from stereotactic vacuum-assisted breast biopsy of a breast mass identified in screening mammography. Percutaneous embolization was planned and guided using 3D reconstructions from computed tomographic angiography, and bleeding was successfully controlled with micro-coil embolization.
Collapse
Affiliation(s)
- Martin Halicek
- Medical College of Georgia at Augusta University, Department of Radiology, Augusta, GA, USA
| | - Chenghao Qian
- University of California Davis, Department of Internal Medicine, Davis, CA, USA
| | - Driss Raissi
- University of Kentucky Chandler Medical Center, Department of Radiology, Lexington, KY, USA
| | - Xiaoqin Wang
- University of Kentucky Chandler Medical Center, Department of Radiology, Lexington, KY, USA
| | | | - William B Bates
- Medical College of Georgia at Augusta University, Department of Radiology, Augusta, GA, USA
| | - Michael Winkler
- Medical College of Georgia at Augusta University, Department of Radiology, Augusta, GA, USA
| |
Collapse
|
10
|
Liang T, Cong S, Yi Z, Liu J, Huang C, Shen J, Pei S, Chen G, Liu Z. Ultrasound-Based Nomogram for Distinguishing Malignant Tumors from Nodular Sclerosing Adenoses in Solid Breast Lesions. JOURNAL OF ULTRASOUND IN MEDICINE : OFFICIAL JOURNAL OF THE AMERICAN INSTITUTE OF ULTRASOUND IN MEDICINE 2021; 40:2189-2200. [PMID: 33438775 DOI: 10.1002/jum.15612] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/19/2020] [Revised: 12/01/2020] [Accepted: 12/14/2020] [Indexed: 06/12/2023]
Abstract
OBJECTIVES Nodular sclerosing adenoses (NSAs) and malignant tumors (MTs) may coexist and are often classified into the same Breast Imaging Reporting and Data System (BI-RADS) category. We aimed to build and validate an ultrasound-based nomogram to distinguish MT from NSA for building a precise sequence of biopsies. MATERIALS AND METHODS The training cohort included 156 patients (156 masses) with NSA or MT at one study institution. We used best subset regression to determine the predictors for building a nomogram from ultrasonic characteristics and patients' age. Model performance and clinical utility were evaluated using Brier score, concordance (C)-index, calibration curve, and decision curve analysis. The independent validation cohort consisted of 162 patients (162 masses) from a separate institution. RESULTS Through best subset regression, we selected 6 predictors to develop nomogram: age, calcification, echogenic rim, vascularity distribution, tumor size, and thickness of breast parenchyma. Brier score and C-index of the nomogram in the training cohort were 0.068 and 0.967 (95% confidence interval [CI]: 0.941-0.993), respectively. In addition, calibration curve demonstrated good agreement between prediction and pathological result. In the validation cohort, the nomogram still obtained a favorable C-index score of 0.951 (95% CI: 0.919-0.983) and fine calibration. Decision curve analysis showed that the model was clinically useful. CONCLUSIONS If multiple NSA and MT masses are present in the same patient and are classified into the same BI-RADS category, our nomogram can be used as a supplement to the BI-RADS category for accurate biopsy of the mass most likely to be MT.
Collapse
Affiliation(s)
- Ting Liang
- The Second School of Clinical Medicine, Southern Medical University, No.253 Gongye Middle Avenue, Guangzhou, Guangdong, People's Republic of China
- Department of Ultrasound, Affiliated Hospital of Guangdong Medical University, No.57 People's Avenue South, Zhanjiang, Guangdong, People's Republic of China
| | - Shuzhen Cong
- Department of Ultrasound, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, No.106 Zhongshan Er Road, Guangzhou, Guangdong, 510080, People's Republic of China
| | - Zongjian Yi
- Department of Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, No.106 Zhongshan Er Road, Guangzhou, Guangdong, 510080, People's Republic of China
| | - Juanjuan Liu
- Department of Ultrasound, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, No.106 Zhongshan Er Road, Guangzhou, Guangdong, 510080, People's Republic of China
| | - Chunwang Huang
- Department of Ultrasound, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, No.106 Zhongshan Er Road, Guangzhou, Guangdong, 510080, People's Republic of China
| | - Junhui Shen
- Department of Anesthesiology, Affiliated Hospital of Guangdong Medical University, No.57 People's Avenue South, Zhanjiang, Guangdong, People's Republic of China
| | - Shufang Pei
- Department of Ultrasound, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, No.106 Zhongshan Er Road, Guangzhou, Guangdong, 510080, People's Republic of China
| | - Gaowen Chen
- The Second School of Clinical Medicine, Southern Medical University, No.253 Gongye Middle Avenue, Guangzhou, Guangdong, People's Republic of China
| | - Zaiyi Liu
- The Second School of Clinical Medicine, Southern Medical University, No.253 Gongye Middle Avenue, Guangzhou, Guangdong, People's Republic of China
- Department of Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, No.106 Zhongshan Er Road, Guangzhou, Guangdong, 510080, People's Republic of China
| |
Collapse
|
11
|
Arfi Rouche J, Jalaguier Coudray A, Roullet S, Poncelet É, Thomassin-Naggara I, de Bazelaire C, Moalla S, Balleyguier C. Micro- et macrobiopsies mammaires chez les patientes sous traitement antithrombotique. IMAGERIE DE LA FEMME 2021. [DOI: 10.1016/j.femme.2021.06.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
12
|
Vijapura CA, Wahab RA, Thakore AG, Mahoney MC. Upright Tomosynthesis-guided Breast Biopsy: Tips, Tricks, and Troubleshooting. Radiographics 2021; 41:1265-1282. [PMID: 34357806 DOI: 10.1148/rg.2021210017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The advent and implementation of digital breast tomosynthesis (DBT) have had a significant effect on breast cancer detection and image-guided breast procedures. DBT has been shown to improve the visualization of architectural distortions and noncalcified masses. With the incorporation of DBT imaging, biopsy of those findings seen only with DBT is feasible, and the need for localization and surgical excision to determine the pathologic diagnosis is avoided. The additional benefits of reduced procedural time, better localization, and increased technical success support the use of DBT for breast biopsy. DBT-guided biopsy can be performed with the patient prone or upright, depending on the table or unit used. Upright positioning enables improved patient comfort, particularly in patients who have restricted mobility, weight-related limitations, and/or difficulty lying prone for an extended period. Upright DBT-guided breast procedures require a cohesive team approach with overlapping radiologist and technologist responsibilities. Since this is a common breast procedure, the radiologist should be familiar with preprocedural considerations, patient preparations, and use of the biopsy equipment. The basic principles of upright DBT-guided breast biopsy are described in this comprehensive review. The various procedural components, including alternative approaches and techniques, are discussed. Tips and tricks for navigating the biopsy procedure to minimize complications, imaging examples of crucial steps, and supporting diagrams are provided. In addition, the challenges of performing upright DBT-guided biopsy, with troubleshooting techniques to ensure a successful procedure, are reviewed. ©RSNA, 2021.
Collapse
Affiliation(s)
- Charmi A Vijapura
- From the Department of Radiology, University of Cincinnati Medical Center, 234 Goodman St, Cincinnati, OH 45219-0772
| | - Rifat A Wahab
- From the Department of Radiology, University of Cincinnati Medical Center, 234 Goodman St, Cincinnati, OH 45219-0772
| | - Atharva G Thakore
- From the Department of Radiology, University of Cincinnati Medical Center, 234 Goodman St, Cincinnati, OH 45219-0772
| | - Mary C Mahoney
- From the Department of Radiology, University of Cincinnati Medical Center, 234 Goodman St, Cincinnati, OH 45219-0772
| |
Collapse
|
13
|
Can supplementary contrast-enhanced MRI of the breast avoid needle biopsies in suspicious microcalcifications seen on mammography? A systematic review and meta-analysis. Breast 2021; 56:53-60. [PMID: 33618160 PMCID: PMC7907894 DOI: 10.1016/j.breast.2021.02.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2020] [Revised: 02/05/2021] [Accepted: 02/06/2021] [Indexed: 11/23/2022] Open
Abstract
Purpose To analyze the rate of potentially avoidable needle biopsies in mammographically suspicious calcifications if supplementary Contrast-Enhanced MRI (CE-MRI) is negative. Methods Using predefined criteria, a systematic review was performed. Studies investigating the use of supplemental CE-MRI in the setting of mammographically suspicious calcifications undergoing stereotactic biopsy and published between 2000 and 2020 were eligible. Two reviewers extracted study characteristics and true positives (TP), false positives, true negatives and false negatives (FN). Specificity, in this setting equaling the number of avoidable biopsies and FN rates were calculated. The maximum pre-test probability at which post-test probabilities of a negative CE-MRI met with BI-RADS benchmarks was determined by a Fagan nomogram. Random-effects models, I2-statistics, Deek’s funnel plot testing and meta-regression were employed. P-values <0.05 were considered significant. Results Thirteen studies investigating 1414 lesions with a cancer prevalence of 43.6% (range: 22.7–66.9%) were included. No publication bias was found (P = 0.91). CE-MRI performed better in pure microcalcification studies compared to those also including associate findings (P < 0.001). In the first group, the pooled rate of avoidable biopsies was 80.6% (95%-CI: 64.6–90.5%) while the overall and invasive cancer FN rates were 3.7% (95%-CI: 1.2–6.2%) and 1.6% (95%-CI 0–3.6%), respectively. Up to a pre-test probability of 22%, the post-test probability did not exceed 2%. Conclusion A negative supplementary CE-MRI could potentially avoid 80.6% of unnecessary stereotactic biopsies in BI-RADS 4 microcalcifications at a cost of 3.7% missed breast cancers, 1.6% invasive. BI-RADS benchmarks for downgrading mammographic calcifications would be met up to a pretest probability of 22%. A negative breast MRI can downgrade up to 80.6% of suspicious microcalcifications, potentially avoiding vacuum-assisted breast biopsies. Up to a pretest probability of 22% , a negative breast MRI result would not exceed the 2% cancer rate required for a BI-RADS 3 category assignment.
Collapse
|
14
|
McMahon P, Reichman M, Dodelzon K. Bleeding risk after percutaneous breast needle biopsy in patients on anticoagulation therapy. Clin Imaging 2020; 70:114-117. [PMID: 33157367 DOI: 10.1016/j.clinimag.2020.09.014] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Revised: 09/07/2020] [Accepted: 09/22/2020] [Indexed: 12/12/2022]
Abstract
Image-guided core needle biopsy (CNB) is the standard of care procedure for tissue diagnosis of suspicious breast lesions. While complications are exceedingly rare, the most common complications include bleeding and hematoma formation. With an increasing number of patients on anticoagulation therapy (AT), it is important to determine whether continuation of these medications during CNB increases bleeding risk. While previous studies have demonstrated the safety in continuation of AT during CNB, American College of Radiology (ACR) guidelines recommend practitioners decide whether cessation is necessary on a case-by-case basis as this may put patients at risk for thromboembolic events. The purpose of this review is to analyze the literature on anticoagulation and bleeding risk during CNB to guide clinical practice.
Collapse
Affiliation(s)
- Paige McMahon
- Weill Cornell Medicine, 1300 York Avenue, New York, NY, 10065, USA.
| | - Melissa Reichman
- Weill Cornell Medicine, Department of Radiology, 525 East 68th street, New York, NY 10065, USA.
| | - Katerina Dodelzon
- Weill Cornell Medicine, Department of Radiology, 525 East 68th street, New York, NY 10065, USA.
| |
Collapse
|
15
|
Bicchierai G, Amato F, Vanzi B, De Benedetto D, Boeri C, Vanzi E, Di Naro F, Bianchi S, Cirone D, Cozzi D, Miele V, Nori J. Which clinical, radiological, histological, and molecular parameters are associated with the absence of enhancement of known breast cancers with Contrast Enhanced Digital Mammography (CEDM)? Breast 2020; 54:15-24. [PMID: 32889303 PMCID: PMC7479440 DOI: 10.1016/j.breast.2020.08.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Revised: 08/07/2020] [Accepted: 08/08/2020] [Indexed: 02/08/2023] Open
Abstract
Background CEDM has demonstrated a diagnostic performance similar to MRI and could have similar limitations in breast cancer (BC) detection. Purpose The aim of our study was to systematically analyze the characteristics of the lesions with the absence of enhancement with CEDMs, called false-negatives (FNs), in order to identify which clinical, radiological, histological and molecular parameters are associated with the absence of enhancement of known BCs with CEDMs, and which types of BC are most likely to cause FNs in CEDMs. We also tried to evaluate which parameters instead increased the probability of showing enhancement in the same context. Materials and methods Included in our study group were 348 women with 348 diagnosed BCs performing CEDM as preoperative staging. Two breast-imaging radiologists reviewed the CEDM exams. The absence of perceptible contrast enhancement at the index cancer site was indicative of an FN CEDM, whereas cases with appreciable enhancement were considered true positives (TPs). Dichotomic variables were analyzed with Fisher’s exact probability test or, when applicable, the chi-square test. Binary logistic regression was performed on variables shown to be significant by the univariate analysis in order to assess the relationship between predictors (independent variables) and TFNs (outcome). Results Enhancement was observed in 317 (91.1%) of the 348 BCs. From the 31 (8.9%) lesions which were FNs, we excluded 12 (38.7%) which showed an artifact generated by the post biopsy hematoma and 6 (19.4%) which were outside the CEDM field of vision. We thus obtained 13 (41.9%) BCs considered “True False Negatives” (TFNs), i.e. BCs which showed no enhancement despite being within the CEDM field of vision and failed to show post biopsy hematoma artifacts. We found that the TFNs frequently have a unifocal disease extension, diameter <10 mm, a lower number of luminal B HER2-subtypes, a higher number of DCIS, and an index lesion with microcalcifications. Conclusions The parameters we found to be associated with no enhancement of known BCs with CEDMs were: unifocal disease extension, DCIS histotype, lesion dimensions <10 mm, and index lesion with microcalcifications. The characteristics that instead increase the probability of showing enhancement were US mass, Luminal B HER2 negative molecular subtype, the presence of an invasive ductal component, and lesion dimensions ≥10 mm. The variables associated with an increased risk of no enhancement were unifocal disease extension, non-classifiable molecular subtype, DCIS histotype, lesion dimensions <10 mm, index lesion represented by microcalcifications. A greater probability of showing enhancement entailed the presence of an invasive ductal component, index lesion represented by ultrasound mass, Luminal B HER2 negative molecular subtype, lesion dimensions ≥10 mm, multifocal disease extension.
Collapse
Affiliation(s)
- Giulia Bicchierai
- Diagnostic Senology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
| | - Francesco Amato
- Radiology Department, Ospedale San Giovanni di Dio, Agrigento, Italy
| | - Bianca Vanzi
- Diagnostic Senology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - Diego De Benedetto
- Diagnostic Senology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - Cecilia Boeri
- Diagnostic Senology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - Ermanno Vanzi
- Diagnostic Senology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - Federica Di Naro
- Diagnostic Senology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - Simonetta Bianchi
- Division of Pathological Anatomy, University of Florence, Florence, Italy
| | - Donatello Cirone
- General Management Staff, Azienda Ospedaliero-Universitaria Careggi Florence, Italy
| | - Diletta Cozzi
- Emergency Radiology Department, Azienda Ospedaliero-Universitaria Careggi Florence, Italy
| | - Vittorio Miele
- Emergency Radiology Department, Azienda Ospedaliero-Universitaria Careggi Florence, Italy
| | - Jacopo Nori
- Diagnostic Senology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| |
Collapse
|
16
|
Abstract
OBJECTIVE. The purpose of this article is to review the literature regarding image-guided breast procedures, including helpful tips and tricks to guide the practicing interventional breast radiologist. CONCLUSION. The successful diagnosis and treatment of breast cancer involves coordination of the multidisciplinary breast team. Optimal procedural skills for image-guided biopsy and preoperative lesion localization are paramount to the radiologists' success.
Collapse
|